Trials / Completed
CompletedNCT01479439
Losartan to Reverse Sickle Nephropathy
A Phase II Trial of Losartan to Reverse Sickle Nephropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Children's Hospital Medical Center, Cincinnati · Academic / Other
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
Sickle cell disease causes kidney damage with increasing age, leading to chronic kidney disease and renal failure in nearly one third of patients with sickle cell disease. Currently, there is no treatment for sickle cell related kidney disease.
Detailed description
The purpose of this research study is to see if losartan can help reduce or reverse damage done to the kidneys of children and adults with Sickle Cell Anemia (SCA) and Sickle Beta-zero (HbSβ0) Thalassemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Losartan | Form: suspension, tablet. Dosage \& frequency: age 6-16 = 0.7mg/kg once daily; age \>16 = 50mg once daily. Duration: 6 months |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2015-11-01
- Completion
- 2015-12-01
- First posted
- 2011-11-24
- Last updated
- 2020-09-29
- Results posted
- 2020-09-29
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01479439. Inclusion in this directory is not an endorsement.